Skip to main content
Fig. 5 | BMC Pulmonary Medicine

Fig. 5

From: NTP42, a novel antagonist of the thromboxane receptor, attenuates experimentally induced pulmonary arterial hypertension

Fig. 5

MCT-induced mast cell infiltration and pulmonary fibrosis is attenuated by NTP42 treatment. Panels a & b show: (a). Pulmonary mast cell density in the ‘No MCT’, vehicle/‘MCT Only’, NTP42, Sildenafil, and Selexipag groups [n = 6, 5, 5, 5 and 6, respectively] and (b). Pulmonary fibrosis [n = 5, 8, 5, 6 and 6, respectively]. All data are expressed as the mean ± SEM. * P ≤ 0.05, ** P ≤ 0.01, *** P ≤ 0.001, **** P ≤ 0.0001 vs. ‘MCT Only’, # P ≤ 0.05 vs. NTP42, according to unpaired Student’s t tests. Panels c & d show: (c). Representative photomicrographs of toluidine blue-stained sections from a randomly selected animal from each group. Images shown were captured at 200× magnification. (d). Representative photomicrographs of trichrome-stained sections from a randomly selected animal from each group. Images shown were captured at 400× magnification. Black scale lines represent 50 μm and 20 μm for toluidine blue-stained and Masson's trichrome-stained sections, respectively. Note that the numbers (n) given in the square brackets refer to the number of input data used for the given parameter following removal of outliers identified using IQR with Tukey fences

Back to article page